Drug either PPIS or H2RA and prokinetics

King Saud University · FDA-approved active Small molecule

Drug either PPIS or H2RA and prokinetics is a Combination antacid and prokinetic agent Small molecule drug developed by King Saud University. It is currently FDA-approved for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Functional dyspepsia with impaired gastric motility. Also known as: Drug treatment, lansoprazole, esomeprazole,pantoprazole,rebeprazole, omeprazole,cimetidine,nizatidine,famotidine,ranitidine,lafutidine.

This is a combination therapy using either proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) to reduce gastric acid, paired with prokinetic agents to enhance gastric motility and accelerate gastric emptying.

This is a combination therapy using either proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) to reduce gastric acid, paired with prokinetic agents to enhance gastric motility and accelerate gastric emptying. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Functional dyspepsia with impaired gastric motility.

At a glance

Generic name	Drug either PPIS or H2RA and prokinetics
Also known as	Drug treatment, lansoprazole, esomeprazole,pantoprazole,rebeprazole, omeprazole,cimetidine,nizatidine,famotidine,ranitidine,lafutidine
Sponsor	King Saud University
Drug class	Combination antacid and prokinetic agent
Target	H+/K+-ATPase (PPIs) or H2 receptor (H2RAs); dopamine antagonist or other prokinetic target
Modality	Small molecule
Therapeutic area	Gastroenterology
Phase	FDA-approved

Mechanism of action

PPIs irreversibly inhibit the H+/K+-ATPase pump in gastric parietal cells, while H2RAs competitively block histamine H2 receptors to reduce acid secretion. Prokinetics (such as metoclopramide or domperidone) enhance gastric muscle contractions and accelerate food movement through the stomach. The combination addresses both acid-related symptoms and motility dysfunction in gastroesophageal reflux disease and related conditions.

Approved indications

• Gastroesophageal reflux disease (GERD)
• Peptic ulcer disease
• Functional dyspepsia with impaired gastric motility

Common side effects

• Headache
• Diarrhea or constipation
• Nausea
• Abdominal pain
• Fatigue

Key clinical trials

• Prophylaxis for Aspiration of Gastric Contents. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Drug either PPIS or H2RA and prokinetics CI brief — competitive landscape report
• Drug either PPIS or H2RA and prokinetics updates RSS · CI watch RSS
• King Saud University portfolio CI

Frequently asked questions about Drug either PPIS or H2RA and prokinetics

What is Drug either PPIS or H2RA and prokinetics?

Drug either PPIS or H2RA and prokinetics is a Combination antacid and prokinetic agent drug developed by King Saud University, indicated for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Functional dyspepsia with impaired gastric motility.

How does Drug either PPIS or H2RA and prokinetics work?

This is a combination therapy using either proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) to reduce gastric acid, paired with prokinetic agents to enhance gastric motility and accelerate gastric emptying.

What is Drug either PPIS or H2RA and prokinetics used for?

Drug either PPIS or H2RA and prokinetics is indicated for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Functional dyspepsia with impaired gastric motility.

Who makes Drug either PPIS or H2RA and prokinetics?

Drug either PPIS or H2RA and prokinetics is developed and marketed by King Saud University (see full King Saud University pipeline at /company/king-saud-university).

Is Drug either PPIS or H2RA and prokinetics also known as anything else?

Drug either PPIS or H2RA and prokinetics is also known as Drug treatment, lansoprazole, esomeprazole,pantoprazole,rebeprazole, omeprazole,cimetidine,nizatidine,famotidine,ranitidine,lafutidine.

What drug class is Drug either PPIS or H2RA and prokinetics in?

Drug either PPIS or H2RA and prokinetics belongs to the Combination antacid and prokinetic agent class. See all Combination antacid and prokinetic agent drugs at /class/combination-antacid-and-prokinetic-agent.

What development phase is Drug either PPIS or H2RA and prokinetics in?

Drug either PPIS or H2RA and prokinetics is FDA-approved (marketed).

What are the side effects of Drug either PPIS or H2RA and prokinetics?

Common side effects of Drug either PPIS or H2RA and prokinetics include Headache, Diarrhea or constipation, Nausea, Abdominal pain, Fatigue.

What does Drug either PPIS or H2RA and prokinetics target?

Drug either PPIS or H2RA and prokinetics targets H+/K+-ATPase (PPIs) or H2 receptor (H2RAs); dopamine antagonist or other prokinetic target and is a Combination antacid and prokinetic agent.

Related

• Drug class: All Combination antacid and prokinetic agent drugs
• Target: All drugs targeting H+/K+-ATPase (PPIs) or H2 receptor (H2RAs); dopamine antagonist or other prokinetic target
• Manufacturer: King Saud University — full pipeline
• Therapeutic area: All drugs in Gastroenterology
• Indication: Drugs for Gastroesophageal reflux disease (GERD)
• Indication: Drugs for Peptic ulcer disease
• Indication: Drugs for Functional dyspepsia with impaired gastric motility
• Also known as: Drug treatment, lansoprazole, esomeprazole,pantoprazole,rebeprazole, omeprazole,cimetidine,nizatidine,famotidine,ranitidine,lafutidine